Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axitinib (Ag-013736) As Second Line Therapy For Metastatic Renal Cell Cancer: Axis Trial

Trial Profile

Axitinib (Ag-013736) As Second Line Therapy For Metastatic Renal Cell Cancer: Axis Trial

Phase of Trial: Phase III

Latest Information Update: 15 Jan 2019

At a glance

  • Drugs Axitinib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms AXIS
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
    • 12 Oct 2017 Results of pooled data from two phase 3 trial ( A6181034 and Axis trial ) assessing important group differences on the functional assessment of cancer therapy-kidney symptom index disease-related symptoms in patients with metastatic renal cell carcinoma, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 11 Oct 2016 Results of retrospective analysis of AXIS trial assessing correlation of longitudinal target-lesions size with progression-free and overall-survival presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top